Evidence map›Paper›PMID 40243589›Full record

ArticleeLife2025

Combinatorial CRISPR screen reveals

Tackhoon Kim, Byung-Sun Park, Soobeen Heo, Heeju Jeon, Jaeyeal Kim, Donghwa Kim, Sang Kook Lee, So-Youn Jung, Sun-Young Kong, Timothy Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. AI-Driven Polypharmacology in Small-Molecule Drug Discovery.International journal of molecular sciences · 2025
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tackhoon KimMedicinal Materials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-7911-6273
Byung-Sun ParkMedicinal Materials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Soobeen HeoTargeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea.
Heeju JeonMedicinal Materials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Jaeyeal KimMedicinal Materials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
Donghwa KimCollege of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul, Republic of Korea.
Sang Kook LeeCollege of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul, Republic of Korea.
So-Youn JungDivision of Breast Surgery, Department of Surgery, National Cancer Center, Goyang, Republic of Korea.
Sun-Young KongTargeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea.
Timothy LuResearch Lab of Electronics, Massachusetts Institute of Technology, Cambridge, United States.

Funding

Korea Institute of Science and Technology 2E32331National Research Foundation of Korea 2020M3A9A5036362National Research Foundation of Korea 2021R1A2C1093499
6 · The paper itself

Abstract

Tyrosine kinases play a crucial role in cell proliferation and survival and are extensively investigated as targets for cancer treatment. However, the efficacy of most tyrosine kinase inhibitors (TKIs) in cancer therapy is limited due to resistance. In this study, we identify a synergistic combination therapy involving TKIs for the treatment of triple negative breast cancer. By employing pairwise tyrosine kinase knockout CRISPR screens, we identify

Indexed as

Antineoplastic AgentsJumonji Domain-Containing Histone DemethylasesProtein Kinase InhibitorsProto-Oncogene Proteins c-fynTriple Negative Breast NeoplasmsAnimalsCell Line, TumorCRISPR-Cas SystemsDrug Resistance, NeoplasmDrug SynergismFemaleHumansMiceAntineoplastic AgentsFYN protein, humanJumonji Domain-Containing Histone DemethylasesProtein Kinase InhibitorsProto-Oncogene Proteins c-fynbreast cancercancer biologyCRISPR screengeneticsgenomicshistone demethylasehumantyrosine kinase

Identifiers

PMID40243589
PMCPMC12005726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.